Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: Results of the PRO-R-IPI study

dc.contributor.author	Panizo, C.
dc.contributor.author	Jaramillo, A.
dc.contributor.author	Gutiérrez, Gonzalo
dc.contributor.author	González Rodríguez, Ana Pilar
dc.date.accessioned	2015-12-21T10:40:04Z
dc.date.available	2015-12-21T10:40:04Z
dc.date.issued	2015
dc.identifier.citation	Clinical Lymphoma, Myeloma and Leukemia, 15(7), p. 398-403 (2015); doi:10.1016/j.clml.2015.02.029
dc.identifier.issn	2152-2650
dc.identifier.uri	http://hdl.handle.net/10651/34198
dc.description.statementofresponsibility	Panizo, C., Rodríguez, A.J., Gutiérrez, G., Díaz, F.J., González-Barca, E., De Oña, R., Grande, C., Sancho, J.M., García-Álvarez, M.F., Sánchez-González, B., Peñalver, F.J., Cannata, J., Espeso, M., Requena, M.J., Gardella, S., Durán, S., González, A.P., Alfonso, A., Caballero, M.D.
dc.format.extent	p. 398-403
dc.language.iso	eng
dc.relation.ispartof	Clinical Lymphoma, Myeloma and Leukemia
dc.rights	© 2015 Elsevier
dc.source	Scopus
dc.source.uri	http://www.scopus.com/inward/record.url?eid=2-s2.0-84937514108&partnerID=40&md5=8a792c8cd953849dfd6fafda6a383ee7
dc.title	Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: Results of the PRO-R-IPI study
dc.type	journal article
dc.identifier.doi	10.1016/j.clml.2015.02.029
dc.relation.publisherversion	http://dx.doi.org/10.1016/j.clml.2015.02.029

Ficheros en el ítem

Ficheros	Tamaño	Formato	Ver
No hay ficheros asociados a este ítem.